Purpose: Transcutaneous oxygen tension (TcpO 2 ) provides information about blood perfusion in the tissue immediately below the skin. These data are valuable in assessing wound healing problems, diagnosing peripheral vascular/arterial insufficiency, and predicting disease progression or the response to therapy. Currently, TcpO 2 is primarily measured using electrochemical skin sensors, which consume oxygen and are prone to calibration errors. The goal of the present study was to develop a reliable method for TcpO 2 measurement in human subjects. Methods: We have developed a novel TcpO 2 oximetry method based on electron paramagnetic resonance (EPR) principles with an oxygen-sensing skin adhesive film, named the superficial perfusion oxygen tension (SPOT) chip. The SPOT chip is a 3-mm diameter, 60-m thick circular film composed of a stable paramagnetic oxygen sensor. The chip is covered with an oxygen-barrier material on one side and secured on the skin by a medical adhesive transfer tape to ensure that only the oxygen that diffuses through the skin surface is measured. The method quantifies TcpO 2 through the linewidth of the EPR spectrum. Results: Repeated measurements using a cohort of 10 healthy human subjects showed that the TcpO 2 measurements were robust, reliable, and reproducible. The 
and reliable method for routine clinical use remains elusive. In the late 1980s, a computerized polarographic needle electrode system, called Eppendorf, was used extensively to assess tumor tissue oxygen levels in the clinic. Its use was limited because it was invasive and unsuitable for repeated measurements. 2 Currently, several techniques based on other principles exist, including fluorescence-quenching, phosphorescence-quenching, near-infrared, and magnetic resonance 3 ;
however, their use for routine clinical applications is limited. An ideal method for routine clinical use must be noninvasive, reliable, repeatable, and able to measure oxygen tension directly (partial pressure of oxygen, pO 2 ). In particular, the method must provide repeated measurements from the region of interest to monitor changes in oxygen tension over the observation or treatment period. Transcutaneous oxygen monitoring (TcOM) is a noninvasive, clinically approved method to obtain skin oxygen levels. 4, 5 The method is quantitative and measures oxygen delivery to the skin from underlying tissue. It has been used to monitor transcutaneous oxygen tension (TcpO 2 ) in the skin, especially for premature infants, but also for adults in the intensive care setting. 6 Physicians also use TcOM to determine whether or not adequate blood flow exists to heal lower extremity wounds, such as venous stasis or diabetic foot ulcers. Vascular surgeons use TcOM measurements to assess the need for amputation and determine the level where the amputation should take place. Unfortunately, the TcOM method has some significant limitations. The method is prone to calibration errors, and the electrode consumes oxygen during measurement and is therefore not capable of measuring low levels of oxygen that may be present in the skin under room temperature. To compensate for this, TcOM uses a heated metal electrode placed directly on the skin. During measurement, the skin beneath the electrode is heated up to 44C, which dilates the vessels in the underlying tissue and increases oxygen permeability. Alternative methods based on optical sensors using fluorescence-, 7 phosphorescence-, [8] [9] [10] or luminescence-quenching 11, 12 are under development to overcome the limitations associated with TcOM. We are developing a novel oximetry method, based on electron paramagnetic resonance (EPR) using oxygen-sensing paramagnetic probes, for deep-tissue and superficial tissue measurements in the clinical setting. 13, 14 The principle of EPR oximetry is based on the paramagnetic characteristics of molecular oxygen, which in its ground state has 2 unpaired electrons and undergoes spin exchange interaction with a paramagnetic EPR spin probe. This process is sensitive to the amount of oxygen present in the local environment, with the relaxation rate of the spin probe increasing as a function of oxygen partial pressure (pO 2 ). The increased spin-spin relaxation rate results in increased linebroadening. The fact that the width of EPR resonance line correlates with oxygen tension has been used in a variety of biological applications. [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] To perform repeated measurements of tissue pO 2 in humans, we have developed a novel class of implantable sensors using stable paramagnetic molecules or crystals embedded in biocompatible polymers. [27] [28] [29] [30] [31] Recently, we have also started using EPR oximetry with an implantable sensor, called OxyChip, for measuring tumor oxygen levels in cancer patients. 32 Initial clinical trial results indicate EPR oximetry could be a reliable and robust tool for clinical oximetry.
The goal of the present study was to develop and evaluate a novel EPR sensor and procedures for noninvasive monitoring of transcutaneous oxygen in human subjects. The method uses a paramagnetic chip that when placed on the skin is highly responsive to superficial perfusion oxygen tension (SPOT). The sensory element of the chip consists of microcrystals of lithium octa-n-butoxynaphthalocyanine (LiNc-BuO) embedded in polydimethylsiloxane (PDMS). The method is noninvasive, highly sensitive to low oxygen levels (hypoxia), and repeatable for long-term tissue oxygen monitoring. In this study, we have performed a preliminary evaluation of the SPOT chip's capabilities using a small (N = 10) cohort of healthy human subjects. We present the results, which demonstrate the potential of this method for use in the clinic where routine monitoring of transcutaneous oxygen is required for prognosis and treatment of patients with perfusion-limited vascular diseases, chronic wounds, or skin malignancies.
| METHODS

| Composition and fabrication of SPOT chip
The oxygen sensor (SPOT chip) is composed of 2 layers, an oxygen-sensing layer made of finely powdered microcrystals of LiNc-BuO embedded in polydimethylsiloxane (PDMS) polymer and an oxygen-barrier film (Figure 1 ). The SPOT chip was fabricated by cast-molding polymerization and embedding processes using platinum silicone elastomer (MED-4210, medical-grade PDMS, from Factor II, Lakeside, AZ) and LiNc-BuO crystals. 28 Microcrystals of LiNc-BuO were synthesized as reported by Pandian et al, 33 suspended in distilled water, sonicated, and evaporated under ambient conditions to produce fine crystals of < 2-m size. The PDMS base and catalyst-cross-linker (supplied with the PDMS elastomer) were mixed in a 10:1 ratio, after which the LiNc-BuO crystals (40% by weight) were added.
After the addition of 10 µL (~1 drop) of platinum crosslinking accelerator (A-317), the heterogeneous dispersion/mixture was outgassed using a vacuum desiccator connected to a vacuum pump. Cast-molding of the product in the form of a thin sheet was made using 2 rectangular (10 × 5 cm) transparent acrylic plates and a spacer film (140 m thick). An oxygen-barrier film (3 M 3750P polypropylene tape, 79 m thickness) was placed on 1 plate, and degassed PDMS/LiNcBuO mixture was transferred and evenly spread on the second plate. The 2 plates, with spacer films on the edges, were pressed together to produce a thin film cured at 70°C overnight. The SPOT chips were obtained by cutting the cured film into circular discs of 3-mm diameter using a Miltex medical biopsy dermal puncher. The thickness of the sensory part of the chip was ~ 60 m. The size and shape of the SPOT can be easily adapted for different applications and measurement conditions, but we observed that this thickness and size of the chip was optimal for the skin measurements: the volume is small enough to enable relatively fast diffusion of oxygen into the sensor, but not too small to prevent enough EPR signal from being detected. The function of the oxygen-barrier backing film is to prevent oxygen diffusion from outside and to protect the integrity of the oxygen-sensing film from uneven contact with the skin.
| Calibration of oxygen and temperature sensitivity
The oxygen sensitivity of the SPOT chip was measured and calibrated using an L-band EPR spectrometer as reported. 32 Briefly, the chip was placed over a small opening of a customdesigned chamber with provisions for gas flow through it. A thermocouple (Omega HH23A type K Omega Engineering, Norwalk, CT) was placed on the chip and covered with an oxygen-barrier film (3 M 1523 polyethylene tape) to prevent outside air from diffusing into the chip and/or chamber. A surface-loop resonator 34 was positioned above the chip for EPR measurements. For calibrations, pre-mixed gases with known O 2 concentration (Airgas USA, Cheshire, CT) were flushed into the calibration chamber until equilibrium is reached, usually in ~ 2-3 min. The EPR spectral width, calculated using a single-line Lorentzian model fitting, was used to construct the calibration curve. The effect of temperature on oxygen-sensitivity (EPR line-width) was determined using preheated gas mixtures and temperature from the thermocouple located on the SPOT chip. The temperature calibrations were performed in the temperature range of 22-45°C.
| Protocol for measurement in human subjects
The study protocol was approved by Dartmouth's Committee for the Protection of Human Subjects (CPHS 28207). The study includes data obtained using 10 healthy volunteers (6 males and 4 females) between the ages of 18 and 63. The exclusion criteria, evaluated by screening questionnaire and interview with potential volunteers, were peripheral vascular disease, diabetes, hypertension, pregnancy, or medical implants that would be affected by a magnetic field. Multiple measurements were made on the same subjects with a new sensor applied each time and they were treated as independent measurements. Because the goal of the study was to establish the SPOT chip technology for transcutaneous pO 2 measurements, we did not consider gender, age, or race in our statistical analysis. Before EPR measurement, the site on the flexor side of forearm or between first and second metatarsal head of foot was cleaned with 70% isopropyl alcohol, and the superficial horny scales were exfoliated by stripping 10 times with an adhesive tape. 35, 36 The SPOT chip was placed on the skin and secured with a single-sided, medically approved, oxygen-barrier tape (12.7 mm diameter; 3 M 1523 polyethylene) coated with a pressure-sensitive acrylate adhesive ( Figure 1D ). The adhesive tape was hypoallergenic, approved for use on human skin, and easily peeled off without causing any discomfort or damage. The adhesive tape held the SPOT chip firmly to the skin, while also acting as another layer of insulation from ambient oxygen. We observed that the SPOT chip was insulated and intact (adhered) to the skin for more than 24 h. In cases where the time course of TcpO 2 was followed, the measurements were started immediately after placement of the SPOT chip. In all other cases, the TcpO 2 measurements were made 60-120 min after placement of the chip to make sure the equilibrium value of skin oxygenation would have been reached. In some cases, multiple chips were placed in different locations on the skin and measured individually. During measurement, a custom-built surface loop resonator with a flexible cable was placed over the chip and secured using an adhesive tape or fixation ring ( Figure 1E ). The flexible cable reduces any artifacts because of voluntary or involuntary motion of the subject during the measurement.
| EPR measurement in human subjects
All EPR measurements on human subjects were made using an L-band spectrometer (clinical scanner) developed by the EPR Center at Dartmouth College. 37 Main components of the hardware (RF bridge, resonator) and software (online line-shape fitting) were customized and tuned to make in vivo EPR oximetry measurements. For measurements in the forearm, the subjects were asked to lay supine with the forearm laid across the chest. For foot measurements, the subjects were seated on a chair with the foot down while the chair was raised and moved into the magnet. Subjects were allowed to rest for 5-10 min before the measurements started. For blood-flow constriction experiments, a phlebotomy tourniquet or blood pressure cuff was applied to the arm or leg where the SPOT chip was placed, proximal to the elbow or knee, respectively. EPR measurements were made continuously for ~ 10 min with the tourniquet applied and for at least an additional 10 min after releasing the tourniquet. For hyperoxygenation experiments, following baseline measurements while the subject was breathing room air, the breathing gas was switched to 100% medical grade oxygen administered via a non-rebreather face mask at a flow rate of 15 L/min. EPR measurements were made continuously for 10 min during hyperoxygenation and for at least an additional 10 min after switching to room-air breathing. The EPR settings for the in vivo measurements were: microwave frequency ~ 1.2 GHz, incident RF power 0.6 mW, scan time 5 s, scan range (dependent on the linewidth of the EPR signal), modulation frequency 21 kHz, modulation amplitude was maintained by the automated software at one-third of EPR line width to prevent over-modulation and artificial line broadening. The skin temperature at the SPOT chip location was monitored during EPR data acquisition. The average skin temperature in the foot of 5 subjects during 61 independent sessions was 34.3 ± 1.1°C before and 33.4 ± 1.6°C after EPR measurement suggesting that the low RF power used did not induce any significant (P = 0.30) heating of the skin.
No effort was made to maintain or modify the skin temperature to avoid any perturbation to the tissue perfusion. Skin humidity was not measured during the measurements. Before placement on the skin, the chips were kept under ambient conditions, room temperature (~22°C) and room air (~160 mmHg); however, after placement of the chip on the skin both the temperature and pO 2 within the chip changes rapidly to reach equilibrium with the skin temperature and TcpO 2 . Because the SPOT chip does not consume oxygen, the ambient oxygen trapped in the chip has to diffuse into the skin before establishing an equilibrium with the transcutaneous oxygen. This process, in the present design of SPOT chip, may take up to 60 min depending on the type of skin and conditions including humidity, temperature, etc. In most cases, the TcpO 2 values reported in this study were measured at least 60 min after placement of the chip. During the interim period, the subjects were free to move around or leave and come back for measurements. Throughout this article, the use of the term "base value" refers to the TcpO 2 measured after establishing equilibrium with the skin oxygen and not ambient oxygen.
| TcOM measurements
The TcOM measurements were performed on the foot using TCM400 transcutaneous pO 2 monitoring system (Radiometer Medical ApS, Denmark) to compare with our SPOT chip technology. A single probe, with temperature set at 44°C, was used on the skin between the fourth and fifth metatarsal heads. An equilibrium period of ~ 30-40 min was taken before the reading was stabilized. The TcOM measurements were always made after EPR measurements to avoid the effect of heating (by TcOM) on the EPR data. Simultaneous measurements were not possible because of differences in the skin temperature in the 2 measurements and also because the TcOM probe head would interfere with the EPR magnetic field.
| Statistical analyses
The statistical analyses were conducted using statistical package R, version 3.4.0. 38 To obtain the equilibrium TcpO 2 for the SPOT chip measurements, the following 3-parameter exponential regression model with the asymptote f(t;a 1 ,a 2 ,a 3 ) = a 2 + (a 1 -a 2 ) × exp(−a 3 × t) was used, where t measures time of the measurement (min). The parameters of the model have the following interpretation: a 1 estimates the TcpO 2 value at the start of the measurements (t = 0), a 2 estimates the equilibrium TcpO 2 , and a 3 estimates the rate at which TcpO 2 approaches the equilibrium level. The 3 parameters are estimated by the nonlinear least squares 39 using function "nls" in R. To compare the precision of TcOM and SPOT chip measurements, the F-test for variances was used with the P-value computed using function "pf" in R. To test the homogeneity of SPOT chip measurements at different locations of the foot, the one-way ANOVA was used with the P-value computed using the R function "ANOVA." To estimate the within and between patient variation of SPOT chip TcpO 2 measurements, the variance component model was used. 40 This model was estimated in R using function "lme" from the library "nlme."
3 | RESULTS
| Oxygen response and calibration of SPOT chip
The paramagnetic crystals of LiNc-BuO in the SPOT chip showed a single-line EPR spectrum with a linear relationship between spectral width and pO 2 in the range 0-160 mmHg ( Figure 2A ). The spectrum also exhibited a linear dependence of width on temperature in the presence of oxygen ( Figure 2B ). Because the skin temperature at the SPOT chip may vary widely depending on the skin and room temperature, it is necessary to calibrate the chip for the skin temperature. We measured the temperature-dependent width under different pO 2 to obtain calibration curves for temperatures in the range 22-45°C ( Figure 2C ). The linear nature of variation of the width with temperature and pO 2 makes it possible to use an appropriate sensitivity calibration for any temperature through the relationship: sensitivity (mG/mmHg) = 16.0-0.161 × T, where T is temperature (°C).
| Time-course of TcpO 2 and its response to changes in underlying tissue
The time to reach equilibrium was determined by continuously monitoring the pO 2 after the SPOT chip was placed on the foot (between the first and second metatarsal heads) of healthy subjects. Figure 3 shows a typical case where a TcpO 2 value of 22 mmHg was obtained in ~ 30 min after placement of the chip. Although this might not be the equilibrium value, we determined whether the chip was responsive to changes in underlying tissue oxygenation. The blood flow to the foot was temporarily constricted using a blood-pressure cuff during which the TcpO 2 progressively declined to ~ 19 mmHg and returned to the pre-constriction value when the blood flow was restored. The results demonstrated the ability of the chip to respond to changes in underlying tissue oxygenation in the foot.
| Response of TcpO 2 to oxygen deprivation and hyperoxygenation
The ability of the SPOT chip to respond to dynamic changes in tissue oxygenation was determined in the forearm skin of healthy subjects. After reaching equilibrium TcpO 2 , blood flow to the forearm was temporarily constricted using a bloodpressure cuff. Figure 4 shows the measurements in a single subject where the TcpO 2 declined from a steady-state base value of 27.1 ± 0.1 mmHg to 19.1 ± 0.1 mmHg in ~ 10 min of constriction and increased to 30.6 ± 0.2 mmHg after restoration of blood flow to the arm. This level was significantly higher than the base value, which is indicative of a reactive hyperemia. It was also observed that subsequent breathing of 100% oxygen, administered through a non-rebreather facemask, resulted in further increase of TcpO 2 to 38.0 ± 0.2 mmHg followed by a slow return toward base value. The results demonstrated the ability of the chip to respond to changes in tissue and transcutaneous oxygenation in the arm.
| Kinetics of SPOT chip pO 2 toward
establishing equilibrium with skin pO 2 When the SPOT chip is placed on the skin, the ambient oxygen trapped in the chip establishes a steep oxygen gradient across the skin resulting in the diffusion of oxygen into the skin before establishing equilibrium with the transcutaneous oxygen. We wanted to determine the kinetics of oxygen exchange and to know whether the information (eg, rate of decay) would be a predictor of equilibrium TcpO 2 .
Immediately after the SPOT chips were applied to the skin of arm or foot of healthy subjects, the temporal changes in chip pO 2 was monitored continuously for up to 60 min. The pO 2 data obtained from the arm (Figure 5A -C) and foot ( Figure  5D -F) showed an exponential decrease of pO 2 toward reaching an equilibrium (base) value. The rate constant of pO 2 drop and equilibrium TcpO 2 value were calculated using a single-exponential decay function with equilibrium model. The average rate constants (mean ± SD) obtained from arm KMIEC Et al. 
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Kinetics of the SPOT chip pO 2 toward establishing equilibrium with skin pO 2 . SPOT chips, kept in room air, were placed on the skin of arm or foot of healthy subjects. Following a delay of 3-5 min while the subject was prepared for EPR measurements, the temporal changes in chip pO 2 was monitored continuously for up to 60 min. The pO 2 data from the arm (A-C) and foot (D-F) show an exponential decrease of pO 2 toward reaching an equilibrium (base) value. The decay rates (inverse of first order rate constant) and equilibrium TcpO 2 values, calculated using a single-exponential decay with equilibrium model, are shown in the respective panels. The quality of fit suggest that the base TcpO 2 values can be predicted from the decay data without having to wait until the equilibrium is reached
F I G U R E 6
TcpO 2 values measured at multiple sites on the foot. TcpO 2 values were measured at 2 different spots in each foot of a healthy subject. Four chips were placed on the skin between the first and second metatarsal heads of the right (R2) and left (L1) foot and the fourth and fifth metatarsal heads of the right (R1) and left (L2) foot as shown in the inset photo. The base pO 2 values from the 4 chips were measured sequentially. The measurements were repeated 4 times on the same subject over a period of 2 weeks using new chips each time. The data, which represent mean ± SD (N = 4), did not show any statistically significant difference (P = 0.932) among the 4 sites measured (5 measurements on 3 subjects) and foot (9 measurements on 3 subjects) measurements were 10.5% ± 2.4% min −1 and 6.7% ± 0.9% min −1 , respectively. The rate constants suggest that equilibrium is reached in ~ 44 min in the arm and 68 min in the foot. Overall, the results established that the base TcpO 2 values can be predicted from the decay data without having to wait until the equilibrium is reached.
| Base values of TcpO 2 measured at multiple sites on the foot
We next determined whether the placement of the chip at different locations on the skin would have any effect on TcpO 2 values. The chips were placed at 4 different sites: the skin between the first, second, fourth, and fifth metatarsal heads of the right and left foot of a healthy subject. As shown in Figure 6 , the TcpO 2 values measured from these 4 sites were comparable (mean ± SD: 10.9 ± 4.3; 10.0 ± 1.1; 11.3 ± 2.4; and 10.6 ± 1.8 mmHg). The one-way ANOVA model and F-test were used to test whether the TcPO 2 measurements at 4 different spots on the foot were statistically different. The test gave a P-value = 0.932 indicating that they were not significantly different from each other. Overall, the results suggest that the skin oxygenation in the foot is fairly uniform and may not be sensitive to minor variations in chip placement for repeated measurements.
| TcpO 2 values measured in the arm of healthy subjects
To evaluate the reliability of SPOT chip oximetry, we determined intra-and inter-person variability of TcpO 2 using a total of 28 measurements made in the flexor side of forearm of 5 healthy subjects over a period of several weeks. A new chip was applied at approximately the same location on the forearm for each measurement and subject. Figure 7 shows the distribution TcpO 2 values within and among the subjects. The data exhibited a substantial variation of TcpO 2 between the subjects, from 7.8 ± 0.8 mmHg to 22.0 ± 1.0 mmHg for each subject. The mean value of all measurements was 12.8 mmHg, with a SD of the repeated measures within the group 3.7 mmHg and between groups 5.4 mmHg. The results demonstrated the accuracy and reliability of transcutaneous oximetry by the SPOT chip.
| TcpO 2 values measured in the foot of healthy subjects
We further determined intra-and inter-person variability of TcpO 2 in the foot of 8 healthy subjects using a total of 81 measurements over a period of several weeks. A new chip was applied at approximately the same location on the foot, between the first and second metatarsal heads for each measurement. The data showed a substantial variation of TcpO 2 between the subjects, from 8.1 ± 0.3 mmHg to 23.4 ± 1.3 mmHg, whereas the variation within each subject was less (Figure 8) . The mean value of all measurements was 15.3 mmHg, with a SD of repeated measures within the group of 3.1 mmHg and that between groups 5.8 mmHg. The results established the ability of SPOT chip oximetry to provide reproducible and reliable TcpO 2 data.
| Correlation of TcpO 2 data obtained using the SPOT chip with TcOM oximetry
We next compared TcpO 2 data measured using the SPOT chip at room temperature with TcOM, which requires heating of the skin while making measurements. We performed repeated TcpO 2 measurements in the foot of 4 healthy subjects over a period of 8 weeks. The SPOT chip measurements were performed with the skin at room temperature, whereas the TcOM measurements were done after heating the skin to 44°C at the location of the electrode. As expected, the TcpO 2 values obtained using TcOM were several folds higher (mean 68.0 ± 2.1 mmHg; N = 17) compared to the SPOT chip (mean 11.0 ± 1.3 mmHg; N = 17) likely because of the skin The average TcpO 2 value (mean ± SD) for each subject. Overall, the results from the foot demonstrate a substantial variation of TcpO 2 among the subjects measured heating that alters both cutaneous blood flow and oxygen permeability. Figure 9A shows a comparison of the 2 groups that indicates a weak correlation (r = 0.40) between the data sets obtained from all subjects. On the other hand, as shown in Figure 9B , the pO 2 values obtained from a single subject showed a better correlation (r = 0.59) between data sets. The Bland-Altman technique to compare SPOT chip with TcOM pO 2 measurements could not be used because this method requires that the compared samples have the same variance, which is not true in our case. Because the mean values of TcpO 2 for TcOM are positively biased because of heating, we compared the precision of the 2 methods using SDs (ie, 8.6 mmHg for TcOM and 5.5 mmHg for the SPOT chip). The one-sided F-test for variances was used for statistical comparison, 41 which gave a P-value of 0.043. According to traditional statistical threshold for the type I error 5%, we reject the null hypothesis that the 2 methods have the same variance and/or precision.
| DISCUSSION
In the present work, we evaluated the SPOT chip technology for measuring transcutaneous oxygen tension in human subjects. The results demonstrated that the SPOT chip method is robust, highly sensitive to low levels of oxygen such as those that occur in pathophysiological conditions, and the pO 2 measurements can be performed at room temperature and at the physiological skin temperature. The SPOT chip technology is a noninvasive method for measuring tissue oxygenation. It can provide clinicians with real-time information about tissue oxygen levels in wounded or injured tissue. This technology could potentially be used to decrease mortality in critically ill patients. Giving surgeons quantitative measurements on levels of tissue oxygenation can help guide their debridement decisions to avoid taking too much tissue (that may increase the difficulty of reconstruction or compromise function of the remaining tissue) or avoid taking too little, which may result in tissue necrosis and infection. It may reduce the number of times a patient must be taken to the operating room for a surgical debridement and decrease the incidence of surgical site infections (SSIs) by reducing the likelihood of leaving behind non-viable tissue. It can be used to monitor the viability of tissue flaps used to close defects because of trauma, cancer, or congenital causes as well as to identify early changes in oxygenation to recognize a compromised flap. An earlier return to the operating room to revise compromised flaps will result in an increased flap salvage rate. The technique could also potentially be used to track changes in vascular supply (e.g., because of hyperbaric oxygen or angiogenic agents). A notable feature of the SPOT chip is its linear and reliable calibration for use at a range of temperatures. We have previously shown that embedding LiNc-BuO crystals in PDMS provides a robust formulation where the calibration of the chip is stable under conditions of high-temperature sterilization and exposures to ionizing radiation. 32 We have also shown that the chip implanted in the rat gastrocnemius muscle was capable of providing repeated and real-time measurements of tissue oxygenation for up to 1 y without any loss of EPR or oxygen sensitivity. Further, no inflammatory or adverse reaction at or around the implantation area was observed thereby establishing its biocompatibility and safety. 32 The effect of temperature on the oxygen sensitivity of SPOT chip is anticipated on the basis that the oxygeninduced exchange broadening occurs exclusively in the gas phase, ie, by diffusion of molecular oxygen into the empty tunnels in the crystal. 42 The temperature studies show a predictable linear behavior, enabling a reliable calibration at measurement temperatures. The EPR detection sensitivity depends on the spin composition of the chip, which is 40% by weight in our case. We observed that this is the highest possible density that we can use reliably for the fabrication of the chip. The oxygen sensitivity, however, is determined from the EPR width and hence is not influenced by the spin content of the chip. The preliminary data collected using SPOT chip establish that the method is reliable and reproducible for real-time measurements in human subjects. The mean TcpO 2 data collected from arm and foot measurements demonstrate that there is less variation within each subject, whereas there is a substantial distribution among the subjects, suggesting that the measured values may be an accurate representation of skin perfusion in individual subjects and not because of measurement uncertainty. The reliability of the measurements is also evident from the correlation between the SPOT chip and TcOM data, despite the fact that these data were collected from a small set of subjects and at 2 different skin temperatures (~33°C for SPOT chip and 44°C for TcOM). Additional measurements with increased number of subjects are needed to establish the relationship between these 2 methods.
The temperature of the skin has a profound effect on the transcutaneous oxygen value. An increase in temperature can increase blood perfusion in the underlying tissue (hyperemia), shift the oxyhemoglobin dissociation curve, and melt lipids in the intact stratum corneum thereby enhancing the diffusion of oxygen across the skin. 36, 43 Electrochemical methods, such as TcOM, take advantage of this effect by increasing the measurement temperature to 40°C and above. Skin oxygen levels at room temperature (where skin temperature is ~ 33°C) has been measured by optical methods, but it is too small for TcOM because of consumption of oxygen by the electrode during measurement. As a result, TcOM measurements show 0 mmHg at normal skin temperature, 44 11 Another study using the LLI method on chronic wounds reported ~ 37 mmHg measured at room temperature 12 ; however, it is questionable whether the measurement on the wound surface would fit the definition of TcpO 2 as the measurement was not on the skin. A TcOM (electrode) device used at 37°C in the abdominal skin (12 subjects) and ankle (20 subjects) reported an average TcpO 2 value of 8.7 ± 11.1 mmHg and 10.8 ± 9.6 mmHg, respectively, which might have underestimated the true TcpO 2 because of its consumption of oxygen. 36 Unlike the optical and TcOM methods, the SPOT chip has a higher sensitivity at lower levels of oxygen because of the fact that EPR sensitivity of detection is inversely proportional to pO 2 , as shown in Figure 1A . Overall, the SPOT chip has the unique capability to measure TcpO 2 at ambient temperature; therefore, it is capable of reporting TcpO 2 under unperturbed conditions. The development and validation of SPOT chip technology would provide a means by which to collect tissue oxygen data noninvasively in a number of clinical situations, including some for which TcOM could not be used. For wound-healing applications, TcOM sensors are placed around the wound, but never inside the wound bed. Because SPOT chips are composed of biocompatible materials and do not actively heat the tissue, they could be placed within the wound bed to obtain data from this region of tissue, which is a key advantage over the TcOM method. Similarly, for plastic surgery applications, SPOT chips could be placed on or within the underlying areas where tissue flaps are placed for reconstructive procedures. The SPOT technology could serve to decrease the incidence of surgical site infections, which will also result in a decrease in mortality and length of hospital stay. It also has the potential to decrease mortality rates for patients in the intensive care unit. It can help guide the treatment of patients with chronic open wounds and make reconstructive surgery more successful by providing better flap monitoring. It may also be used for ventilated patients as a marker for arterial pO 2 , saving on taking blood samples. SPOT technology could be used to track changes in vascular perfusion over time because of interventions such as stents, angioplasties, angiogenic agents, stem-cell therapy, or hyperbaric oxygen treatment. Despite the advantages of the SPOT chip method for making surface or transcutaneous pO 2 measurements, translation of the technology for routine clinical use will require additional efforts including modifying the currently accepted clinical practice of using TcOM data. Most importantly, because the SPOT chip will be used at ambient temperatures (without heating of the skin) the interpretation of the pO 2 data as to hypoxia or normoxia would require rescaling of the hypoxia threshold for proper diagnostic or prognostic decision making by the clinician.
| CONCLUSIONS
We have performed a preliminary evaluation and testing of SPOT chip technology for measurement of transcutaneous oxygen tension in human subjects. The method is noninvasive and highly sensitive to low oxygen levels, such as those that occur in pathophysiological conditions. Initial measurements in human subjects have demonstrated that the SPOT chip can be used to measure transcutaneous pO 2 under ambient conditions. Overall, the study established the SPOT chip as a promising superficial tissue oximetry probe with potential applications in the clinic.
